Earlier this year a megamerger between Quintiles, the world’s largest CRO, and healthcare data and consultancy firm IMS was announced, with the combined company branded as Quintiles IMS. With a
Controversial DNA sequencing company 23andMe announced the first of 10 deals to be signed with large biotech and pharma firms on Tuesday January 6. Their $60 million partnership with Genentech
